ImmuneSensor Therapeutics: Funding, Investors & Team (Sep 2026)
ImmuneSensor is developing novel medicines that target the cGAS (cyclic GMP-AMP synthase) - STING (stimulator of interferon genes) pathway of the innate immune system to treat cancer and autoimmune diseases. The Company has licensed technologies from the laboratory of Dr. Zhijian "James" Chen, Professor of Molecular Biology at the University of Texas Southwestern Medical Center and Investigator of Howard Hughes Medical Institute. Dr. Chen discovered cGAS and its product cGAMP, which activates STING to stimulate immune responses. These discoveries form the technological foundation of ImmuneSensor. The company's pipeline consists of both STING activators to boost anticancer immunity and also cGAS inhibitors to suppress overactivated autoimmunity. ImmuneSensor's lead program, IMSA101 is a STING activator currently in clinical development for cancer therapy.
ImmuneSensor Therapeutics has raised $26.1M across 2 funding rounds on record, the most recent an undisclosed round of $10.0M announced in Dec 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ImmuneSensor Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2022.
ImmuneSensor Therapeutics Funding Rounds
ImmuneSensor Therapeutics raised $16.1M in a Grant announced in Sep 2022.
3 months later, an undisclosed round of $10.0M was announced in Dec 2022.
ImmuneSensor Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
ImmuneSensor Therapeutics Funding Compared to Other Biotechnology Startups
ImmuneSensor Therapeutics' latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ImmuneSensor Therapeutics in Biotechnology and Dallas
Companies Similar to ImmuneSensor Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
ImmuneSensor Therapeutics Funding FAQs
What does ImmuneSensor Therapeutics do?
ImmuneSensor is developing novel medicines that target the cGAS (cyclic GMP-AMP synthase) - STING (stimulator of interferon genes) pathway of the innate immune system to treat cancer and autoimmune diseases. The Company has licensed technologies from the laboratory of Dr. Zhijian "James" Chen, Professor of Molecular Biology at the University of Texas Southwestern Medical Center and Investigator of Howard Hughes Medical Institute. Dr. Chen discovered cGAS and its product cGAMP, which activates STING to stimulate immune responses. These discoveries form the technological foundation of ImmuneSensor. The company's pipeline consists of both STING activators to boost anticancer immunity and also cGAS inhibitors to suppress overactivated autoimmunity. ImmuneSensor's lead program, IMSA101 is a STING activator currently in clinical development for cancer therapy.
How much funding has ImmuneSensor Therapeutics raised?
ImmuneSensor Therapeutics has raised $26.1M across 2 rounds on record. The most recent is an undisclosed round of $10.0M announced in Dec 2022.
When did ImmuneSensor Therapeutics last raise funding?
ImmuneSensor Therapeutics' most recent funding round on record is an undisclosed round of $10.0M, announced in Dec 2022.
Who founded ImmuneSensor Therapeutics?
FundedIQ lists Qingsong Jet Li (Founder) at ImmuneSensor Therapeutics.
Where is ImmuneSensor Therapeutics headquartered?
ImmuneSensor Therapeutics is based in Dallas, Texas, United States.
How many employees does ImmuneSensor Therapeutics have?
ImmuneSensor Therapeutics is in the 1-10 employee band.
How does ImmuneSensor Therapeutics' funding compare to other Biotechnology startups?
ImmuneSensor Therapeutics' latest round of $10.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's ImmuneSensor Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ImmuneSensor Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.